Literature DB >> 20411291

Hyperuricemia and metabolic syndrome: associations with chronic kidney disease.

Lai-Chu See1, Chang-Fu Kuo, Fang-Hsiu Chuang, Yu-Ming Shen, Yu-Shien Ko, Yu-Ming Chen, Kuang-Hui Yu.   

Abstract

The effects of serum uric acid (SUA) and metabolic syndrome on chronic kidney disease (CKD) remain controversial. This study grouped subjects according to a combination of their uric acid and metabolic syndrome status and investigated the association between these groups and CKD to clarify the relationships of SUA and metabolic syndrome to CKD. This survey analyzed data from 81,799 adults (45,148 men and 36,651 women) who underwent health examinations at Chang Gung Memorial Hospital, in northern Taiwan, from 2000 through 2007. Hyperuricemia was defined as an SUA greater than 7.7 mg/dL in men or greater than 6.6 mg/dL in women. Patients were classified by uric acid-metabolic syndrome status as follows: A = no hyperuricemia and no metabolic syndrome, B = presence of metabolic syndrome but not hyperuricemia, C = presence of hyperuricemia but no metabolic syndrome, and D = presence of both hyperuricemia and metabolic syndrome. Kidney function was assessed in terms of the estimated glomerular filtration rate (eGFR) by using the Modification of Diet in Renal Disease Study equation modified for Chinese. CKD was defined as an eGFR <60 mL/min/1.73 m(2). The prevalences of hyperuricemia, metabolic syndrome, and CKD were 22.8% (26.3% in men and 18.6% in women), 13.5% (15.0% in men and 11.6% in women), and 2.2% (2.1% in men and 2.2% in women), respectively. In men, the age-adjusted odds ratios for CKD, with group A as reference, were 1.95 for group B, 4.86 for group C, and 5.85 for group D. In women, the age-adjusted odds ratios were 1.96 for group B, 6.66 for group C, and 9.01 for group D. Hyperuricemia is strongly associated with CKD, independent of the presence of metabolic syndrome.

Entities:  

Mesh:

Year:  2010        PMID: 20411291     DOI: 10.1007/s10067-010-1461-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  47 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960.

Authors:  W M MIKKELSEN; H J DODGE; H VALKENBURG
Journal:  Am J Med       Date:  1965-08       Impact factor: 4.965

3.  Prevalence of hyperuricemia and its relationship with metabolic syndrome in Thai adults receiving annual health exams.

Authors:  Vitool Lohsoonthorn; Bodi Dhanamun; Michelle A Williams
Journal:  Arch Med Res       Date:  2006-10       Impact factor: 2.235

4.  Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome.

Authors:  Tae Woo Yoo; Ki Chul Sung; Hun Sub Shin; Byung Jin Kim; Bum Soo Kim; Jin Ho Kang; Man Ho Lee; Jung Ro Park; Hyang Kim; Eun Jung Rhee; Won Young Lee; Sun Woo Kim; Seung Ho Ryu; Dong Geuk Keum
Journal:  Circ J       Date:  2005-08       Impact factor: 2.993

5.  Studies on the mechanism of fructose-induced hyperuricemia in man.

Authors:  I H Fox; W N Kelley
Journal:  Adv Exp Med Biol       Date:  1974       Impact factor: 2.622

Review 6.  Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.

Authors:  Richard J Johnson; Mark S Segal; Yuri Sautin; Takahiko Nakagawa; Daniel I Feig; Duk-Hee Kang; Michael S Gersch; Steven Benner; Laura G Sánchez-Lozada
Journal:  Am J Clin Nutr       Date:  2007-10       Impact factor: 7.045

7.  Uric acid and incident kidney disease in the community.

Authors:  Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey
Journal:  J Am Soc Nephrol       Date:  2008-03-12       Impact factor: 10.121

8.  Prevalence of the metabolic syndrome in individuals with hyperuricemia.

Authors:  Hyon K Choi; Earl S Ford
Journal:  Am J Med       Date:  2007-05       Impact factor: 4.965

9.  Uric acid and the development of metabolic syndrome in women and men.

Authors:  Xuemei Sui; Timothy S Church; Rebecca A Meriwether; Felipe Lobelo; Steven N Blair
Journal:  Metabolism       Date:  2008-06       Impact factor: 8.694

Review 10.  The conundrum of hyperuricemia, metabolic syndrome, and renal disease.

Authors:  Takahiko Nakagawa; Pietro Cirillo; Waichi Sato; Michael Gersch; Yuri Sautin; Carlos Roncal; Wei Mu; L Gabriela Sánchez-Lozada; Richard J Johnson
Journal:  Intern Emerg Med       Date:  2008-03-05       Impact factor: 3.397

View more
  10 in total

1.  Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease.

Authors:  Hakan Nacak; Merel van Diepen; Abdul R Qureshi; Juan J Carrero; Theo Stijnen; Friedo W Dekker; Marie Evans
Journal:  Nephrol Dial Transplant       Date:  2015-07-16       Impact factor: 5.992

2.  Risk of end-stage renal disease associated with gout: a nationwide population study.

Authors:  Kuang-Hui Yu; Chang-Fu Kuo; Shue-Fen Luo; Lai-Chu See; I-Jun Chou; Hsiao-Chun Chang; Meng-Jiun Chiou
Journal:  Arthritis Res Ther       Date:  2012-04-18       Impact factor: 5.156

3.  Longitudinal changes in uric acid concentration and their relationship with chronic kidney disease progression in children and adolescents.

Authors:  George J Schwartz; Jennifer L Roem; Stephen R Hooper; Susan L Furth; Donald J Weaver; Bradley A Warady; Michael F Schneider
Journal:  Pediatr Nephrol       Date:  2022-06-01       Impact factor: 3.714

4.  Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials.

Authors:  Robert A Yood; Faith D Ottery; William Irish; Marsha Wolfson
Journal:  BMC Res Notes       Date:  2014-01-21

Review 5.  Thoracic cord compression due to ligamentum flavum gouty tophus: a case report and literature review.

Authors:  Z-F Zheng; H-L Shi; Y Xing; D Li; J-Y Jia; S Lin
Journal:  Spinal Cord       Date:  2015-06-16       Impact factor: 2.772

6.  Association of self-reported snoring and hyperuricaemia: a large cross-sectional study in Chongqing, China.

Authors:  Ting Chen; Xianbin Ding; Wenge Tang; Liling Chen; Deqiang Mao; Lingling Song; Xuemei Lian
Journal:  BMJ Open       Date:  2022-04-01       Impact factor: 2.692

Review 7.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

8.  Alcohol consumption is inversely associated with stage 3 chronic kidney disease in middle-aged Taiwanese men.

Authors:  Yueh-Han Hsu; Hsiang-Chu Pai; Yao-Mao Chang; Wen-Hsin Liu; Chih-Cheng Hsu
Journal:  BMC Nephrol       Date:  2013-11-17       Impact factor: 2.388

9.  Clinical epidemiology of reduced kidney function among elderly male fishing and agricultural population in Taipei, Taiwan.

Authors:  Chi-Mei Kuo; Wu-Hsiung Chien; Hsi-Che Shen; Yi-Chun Hu; Yu-Fen Chen; Tao-Hsin Tung
Journal:  Biomed Res Int       Date:  2013-11-13       Impact factor: 3.411

10.  Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia.

Authors:  Lai-Chu See; Chang-Fu Kuo; Kuang-Hui Yu; Shue-Fen Luo; I-Jun Chou; Yu-Shien Ko; Meng-Jiun Chiou; Jia-Rou Liu
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.